Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
LENZ
$12.82
$
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Next Earnings
2026-02-25
Beta
0.49228668
Average Volume
Market Cap
Last Dividend
CIK
0001815776
ISIN
US52635N1037
CUSIP
52635N103
CEO
Evert Schimmelpennink
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
6
IPO Date
2024-03-22
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| LENZ Therapeutics to Present at Upcoming Investor Conferences | SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: | GlobeNewsWire | 2026-02-23 08:00:00 |
| Calamos Timpani Small Cap Growth Fund Q4 2025 Contributors And Detractors | For the quarter ended December 31, 2025, the fund returned 3.77% (Class I shares at NAV), outperforming the Russell 2000 Growth Index return of 1.22%. Lumentum's stock strength in Q4 2025 was driven by a clean earnings beat and accelerating momentum in AI-related optical demand. Stride's common stock declined -56% for the quarter, dropping significantly after the earnings release, even as the company beat EPS and revenue expectations. | Seeking Alpha | 2026-02-12 02:00:00 |
| Analysts Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Target Price at $56.40 | LENZ Therapeutics, Inc. (NASDAQ: LENZ - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The | Defense World | 2026-02-08 01:32:46 |
| New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug | On Wednesday, the U.S. Food and Drug Administration (FDA) approved Tenpoint Therapeutics Ltd.'s Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, the first and only dual-agent eye drop for presbyopia in adults. | Benzinga | 2026-01-30 13:02:55 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ | NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2026-01-22 10:00:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ | NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“LENZ” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. | GlobeNewsWire | 2026-01-20 16:37:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ | NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2026-01-15 10:00:00 |
| LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign | Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours | GlobeNewsWire | 2026-01-14 08:30:00 |
| LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $56.40 Consensus PT from Brokerages | LENZ Therapeutics, Inc. (NASDAQ: LENZ - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to | Defense World | 2026-01-14 02:16:55 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ | NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“LENZ” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. | GlobeNewsWire | 2026-01-13 16:39:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ | NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2026-01-08 10:00:00 |
| LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates | Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 | GlobeNewsWire | 2026-01-07 17:08:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ | NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“LENZ” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. | GlobeNewsWire | 2026-01-06 11:44:00 |
| LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East | SAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing & Consulting FZCO (“Lunatus”) today announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZTM for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. | GlobeNewsWire | 2026-01-05 08:00:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ | NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2026-01-01 10:00:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ | NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“LENZ” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. | GlobeNewsWire | 2025-12-30 12:45:00 |
| LENZ Therapeutics: Was That A Market Overreaction? | LENZ Therapeutics, Inc. shares fell ~30% after a reported adverse event with VIZZ, but I do not view this as thesis-destroying. VIZZ offers superior efficacy and duration versus competitors, yet faces potentially slow market adoption and entrenched alternatives like glasses, contacts, and LASIK. LENZ's $3 billion market opportunity is plausible but hinges on shifting consumer behavior and overcoming negative sentiment from recent safety news. | Seeking Alpha | 2025-12-17 09:02:19 |
| LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year Low – Should You Sell? | LENZ Therapeutics, Inc. (NASDAQ: LENZ - Get Free Report) reached a new 52-week low during trading on Saturday. The company traded as low as $15.70 and last traded at $18.14, with a volume of 6626587 shares trading hands. The stock had previously closed at $24.50. Analyst Upgrades and Downgrades A number of equities analysts recently | Defense World | 2025-12-15 01:00:49 |
| LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Seeking Alpha | 2025-12-04 13:58:49 |
| LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia | Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ | GlobeNewsWire | 2025-12-01 08:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-05 | 2026-02-05 | View Filing |
| SC 13G/A | 2026-01-21 | 2026-01-21 | View Filing |
| 8-K | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 8-K | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13D/A | 2025-11-10 | 2025-11-10 | View Filing |
| 4 | 2025-11-10 | 2025-11-10 | View Filing |
| 4 | 2025-11-07 | 2025-11-07 | View Filing |
| SC 13D/A | 2025-11-07 | 2025-11-07 | View Filing |
| SC 13G | 2025-11-07 | 2025-11-07 | View Filing |
| 10-Q | 2025-11-05 | 2025-11-05 | View Filing |
| 8-K | 2025-11-05 | 2025-11-05 | View Filing |
| SC 13G | 2025-10-17 | 2025-10-17 | View Filing |
| 8-K | 2025-10-08 | 2025-10-08 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 8-K | 2025-09-30 | 2025-09-30 | View Filing |
| 4 | 2025-09-22 | 2025-09-22 | View Filing |
| SC 13D/A | 2025-09-22 | 2025-09-22 | View Filing |
| 4 | 2025-08-26 | 2025-08-26 | View Filing |
| SC 13D/A | 2025-08-20 | 2025-08-20 | View Filing |
| 4 | 2025-08-19 | 2025-08-19 | View Filing |
| 8-K | 2025-07-31 | 2025-07-31 | View Filing |
| 10-Q | 2025-07-30 | 2025-07-30 | View Filing |
| 8-K | 2025-07-30 | 2025-07-30 | View Filing |
| SC 13D/A | 2025-07-14 | 2025-07-14 | View Filing |
| 4 | 2025-07-14 | 2025-07-14 | View Filing |
| 4 | 2025-07-01 | 2025-07-01 | View Filing |
| SC 13D/A | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| SC 13D/A | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 8-K | 2025-06-10 | 2025-06-10 | View Filing |
| SC 13D/A | 2025-05-09 | 2025-05-09 | View Filing |
| 10-Q | 2025-05-07 | 2025-05-07 | View Filing |
| 8-K | 2025-05-07 | 2025-05-07 | View Filing |
| ARS | 2025-04-28 | 2025-04-28 | View Filing |
| DEFA14A | 2025-04-28 | 2025-04-28 | View Filing |
| DEF 14A | 2025-04-28 | 2025-04-28 | View Filing |
| 8-K | 2025-04-15 | 2025-04-15 | View Filing |
| EFFECT | 2025-04-14 | 2025-04-15 | View Filing |
| EFFECT | 2025-04-14 | 2025-04-15 | View Filing |
| 424B5 | 2025-04-14 | 2025-04-14 | View Filing |
| 424B3 | 2025-04-14 | 2025-04-14 | View Filing |
| CORRESP | 2025-04-10 | 2025-04-10 | View Filing |
| CORRESP | 2025-04-10 | 2025-04-10 | View Filing |
| UPLOAD | 2025-04-10 | 2025-04-10 | View Filing |
| UPLOAD | 2025-04-10 | 2025-04-10 | View Filing |
| 4 | 2025-04-09 | 2025-04-09 | View Filing |
| 424B3 | 2025-04-09 | 2025-04-09 | View Filing |
| 424B3 | 2025-04-09 | 2025-04-09 | View Filing |
| EFFECT | 2025-04-08 | 2025-04-09 | View Filing |
| EFFECT | 2025-04-08 | 2025-04-09 | View Filing |
| 8-K | 2025-04-04 | 2025-04-04 | View Filing |
| S-3 | 2025-04-04 | 2025-04-04 | View Filing |
| S-3 | 2025-04-04 | 2025-04-04 | View Filing |
| POS AM | 2025-04-04 | 2025-04-04 | View Filing |
| POS AM | 2025-04-04 | 2025-04-04 | View Filing |
| SC 13G | 2025-03-27 | 2025-03-27 | View Filing |
| S-8 | 2025-03-19 | 2025-03-19 | View Filing |
| 10-K | 2025-03-19 | 2025-03-19 | View Filing |
| 8-K | 2025-03-19 | 2025-03-19 | View Filing |
| 4 | 2025-03-07 | 2025-03-07 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2024-12-17 | 2024-12-18 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13D/A | 2024-11-08 | 2024-11-08 | View Filing |
| 424B3 | 2024-11-06 | 2024-11-06 | View Filing |
| 424B3 | 2024-11-06 | 2024-11-06 | View Filing |
| 10-Q | 2024-11-06 | 2024-11-06 | View Filing |
| 8-K | 2024-11-06 | 2024-11-06 | View Filing |
| 424B3 | 2024-10-28 | 2024-10-28 | View Filing |
| 424B3 | 2024-10-28 | 2024-10-28 | View Filing |
| 8-K | 2024-10-28 | 2024-10-28 | View Filing |
| EFFECT | 2024-09-19 | 2024-09-20 | View Filing |
| 424B3 | 2024-09-19 | 2024-09-19 | View Filing |
| CORRESP | 2024-09-17 | 2024-09-17 | View Filing |
| UPLOAD | 2024-09-13 | 2024-09-13 | View Filing |
| S-1 | 2024-09-11 | 2024-09-11 | View Filing |
| 424B3 | 2024-08-14 | 2024-08-14 | View Filing |
| 10-Q | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-08-14 | 2024-08-14 | View Filing |
| 424B3 | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| RSI Overbought Strategy | 31.51% | 1.35 | 6 | 1.39 | 2.22 | 42.37 |
| Hull Moving Average Strategy | 20.51% | 0.97 | 38 | 0.64 | 0.64 | 31.38 |
| Bull Bias | 16.72% | 0.99 | 39 | 0.37 | 0.29 | 27.59 |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | x | xx | xxxxx | x | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |